For men with metastatic castration-resistant prostate cancer, the approval of lutetium-177 PSMA-617 represented a meaningful advance in targeted therapy — but clinical trial populations rarely capture the full spectrum of patients treated once a drug reaches widespread use. A real-world pharmacovigilance analysis now surfaces adverse event patterns that the original label did not fully anticipate, with implications for how oncologists and their patients weigh benefit against risk.
Drawing on the FDA Adverse Event Reporting System (FAERS) from April 2022 through June 2024, investigators applied four disproportionality algorithms — reporting odds ratio, proportional reporting ratio, MGPS, and BCPNN — to 870 lutetium-177 PSMA-617-linked reports extracted from a database exceeding 3.8 million entries. Established toxicities such as fatigue, anemia, thrombocytopenia, and nausea were confirmed. More notably, signals emerged for conditions absent from current labeling: loss of libido, hydronephrosis, supraventricular tachycardia, tumor lysis syndrome, and tumor flare. In patients over 85, the risk profile shifted considerably, with elevated signals for stomatitis, pneumonia, leukopenia, and sepsis. The median time to adverse event onset was 55 days, with an interquartile range of 24 to 124 days — suggesting a monitoring window that extends well beyond the acute post-infusion period.
FAERS-based analyses carry inherent structural limitations: reporting is voluntary, subject to duplicate entries, and lacks denominator data on total treated patients, making incidence estimation unreliable. Causal inference is not possible from disproportionality statistics alone. Nevertheless, this type of pharmacovigilance work serves a valuable hypothesis-generating function. The hydronephrosis and supraventricular tachycardia signals, in particular, warrant prospective investigation given that neither is prominently flagged in current prescribing guidance. The age-stratified findings are especially clinically relevant — older patients with mCRPC represent a meaningful real-world cohort, and the sepsis and pneumonia signals suggest that immunosuppressive burden may be underappreciated in this demographic. Overall, this analysis is incrementally important: confirmatory in some areas, and usefully provocative in others.